risperidone sold brand name risperdal among others atypical used treat schizophrenia bipolar taken either mouth injection subcutaneous injectable versions longacting last common side effects include severe depression movement problems sleepiness dizziness trouble seeing constipation increased serious side effects may include potentially permanent movement disorder tardive dyskinesia well neuroleptic malignant syndrome increased risk suicide high blood sugar older people psychosis result dementia may increase risk unknown safe use mechanism action entirely clear believed related action dopamine serotonin study risperidone began late approved sale united states world health organizations list essential available generic commonly prescribed medication united states million risperidone mainly used treatment schizophrenia bipolar disorder irritability associated risperidone effective treating psychogenic polydipsia acute exacerbations studies evaluating utility risperidone mouth maintenance therapy reached varying conclusions systematic review concluded evidence strong risperidone effective firstgeneration antipsychotics haloperidol evidence directly supporting superiority placebo review concluded risperidone effective relapse prevention first secondgeneration antipsychotics exception olanzapine cochrane review suggests risperidone reduces overall symptoms schizophrenia firm conclusions difficult make due lowquality evidence data information scarce poorly reported probably biased favour risperidone half included trials developed drug companies article raises concerns regarding serious side effects risperidone cochrane review compared risperidone atypical antipsychotics olanzapine longacting injectable formulations antipsychotic drugs provide improved compliance therapy reduce relapse rates relative oral efficacy risperidone longacting injection appears similar longacting injectable forms firstgeneration secondgeneration antipsychotics including risperidone effective treatment manic symptoms acute manic mixed exacerbations bipolar children adolescents risperidone may effective lithium divalproex metabolic side maintenance therapy longacting injectable risperidone effective prevention manic episodes depressive longacting injectable form risperidone may advantageous longacting firstgeneration antipsychotics better tolerated fewer extrapyramidal effects long acting injectable formulations firstgeneration antipsychotics may increase risk compared placebo risperidone treatment reduces certain problematic behaviors autistic children including aggression toward others selfinjury challenging behavior rapid mood evidence efficacy appears greater alternative pharmacological weight gain important adverse authors recommend limiting use risperidone aripiprazole challenging behavioral disturbances order minimize risk druginduced adverse evidence efficacy risperidone autistic adolescents young adults less antipsychotic medications risperidone slight benefit people dementia linked higher incidence death increased risk death treatment dementiarelated psychosis risperidone fda approved carries black box however many jurisdictions regularly use control severe aggression psychosis dementia nonpharmacological interventions failed pharmaceutical regulators approved use risperidone demonstrated clinical benefit augmentation agent management unipolar nonpsychotic treatmentresistant depression alongside antidepressant atypical antipsychotics risperidone among common augments antidepressant therapy usage occurs offlabel jurisdictions risk adverse effects eg weight gain movement disorders must carefully weighed clinical risperidone shown promise treating therapyresistant obsessivecompulsive disorder serotonin reuptake inhibitors alone risperidone proven effective treatment attention deficit hyperactivity disorder especially cases another mental risperidone demonstrated benefit treatment eating disorders personality disorders except limited evidence schizotypal personality available forms risperidone include tablet oral dissolving tablet oral solution powder solvent suspension common side effects include movement problems sleepiness dizziness trouble seeing constipation increased people gained baseline weight depending serious side effects may include potentially permanent movement disorder tardive dyskinesia well neuroleptic malignant syndrome increased risk suicide high blood sugar older people psychosis result dementia may increase risk atypical antipsychotics appear lower rate movement problems compared typical antipsychotics risperidone high risk movement problems among atypical antipsychotics however associated greater amount weight gain metabolic side british national formulary recommends gradual withdrawal discontinuing antipsychotic treatment avoid acute withdrawal syndrome rapid argued additional somatic psychiatric symptoms associated dopaminergic supersensitivity including dyskinesia acute psychosis common features withdrawal individuals treated led suggest withdrawal process might schizomimetic producing schizophrenialike symptoms even previously healthy patients indicating possible pharmacological origin mental illness yet unknown percentage patients currently previously treated antipsychotics question unresolved remains highly controversial issue among professionals medical mental health communities well older people dementiarelated psychosis higher risk risperidone classified qualitatively atypical antipsychotic agent relatively low incidence extrapyramidal side effects given low doses pronounced serotonin antagonism dopamine antagonism risperidone contains functional groups benzisoxazole piperidine part molecular structure although butyrophenone developed structures benperidol ketanserin basis actions several serotonin receptor subtypes linked weight gain linked antipsychotic action relief extrapyramidal side effects experienced typical found damino acid oxidase enzyme catalyses breakdown damino acids eg dalanine dserine neurotransmitters inhibited risperidone acts following receptors dopamine receptors drug antagonist well family receptors selectivity family tight binding properties means long halflife like antipsychotics risperidone blocks mesolimbic pathway prefrontal cortex limbic pathway tuberoinfundibular pathway central nervous system risperidone may induce extrapyramidal side effects akathisia tremors associated diminished dopaminergic activity striatum also cause sexual side effects galactorrhoea infertility gynecomastia chronic use reduced bone mineral density leading breaks associated increased prolactin serotonin receptors important pharmalogical function compensate dopamine blockingmedical citation needed alpha adrenergic receptors action accounts orthostatic hypotensive effects perhaps sedating effects alpha adrenergic receptors risperidones action receptors may cause greater positive negative affective cognitive symptom histamine receptors effects receptors account sedation reduction vigilance may also lead drowsiness weight voltagegated sodium channels accumulates synaptic vesicles risperidone inhibits voltagegated sodium channels clinically used risperidone undergoes hepatic metabolism renal excretion lower doses recommended patients severe liver kidney active metabolite risperidone paliperidone also used medical source risperidone approved united states food drug administration fda treatment fda approved risperidone shortterm treatment mixed manic states associated bipolar disorder fda approved risperidone treatment irritability autistic children fdas decision based part study autistic people severe enduring problems violent meltdowns aggression selfinjury risperidone recommended autistic people mild aggression explosive behavior without enduring august risperidone approved drug agent available treatment schizophrenia youths ages also approved day treatment bipolar disorder youths children ages joining lithium december committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product okedi intended treatment schizophrenia adults tolerability effectiveness established oral applicant medicinal product laboratorios farmac√©uticos rovi risperidone approved medical use european union february april johnson johnson jj subsidiary janssen pharmaceuticals inc fined billion downplaying multiple risks associated verdict later reversed arkansas state supreme august johnson johnson agreed pay million us states order settle claims promoted risperidone paliperidone offlabel uses including dementia anger management november jj fined billion illegally marketing risperidone use people steven brill wrote investigative journalism piece jj huffington post focused jjs marketing jj faced numerous civil lawsuits behalf children prescribed risperidone grew breasts condition called gynecomastia july cases pennsylvania state court philadelphia february verdict jj million awarded man alabama million verdict jj november million verdict october jury awarded pennsylvania man billion verdict janssens patent risperidone expired december opening market cheaper generic versions companies janssens exclusive marketing rights expired june result pediatric extension available many brand names risperidone available tablet oral solution ampule depot brand names include risperdal risperdal consta risperdal mtab risperdal quicklets risperlet okedi media related risperidone wikimedia commons httpsenwikipediaorgwikirisperidone